Cantor Fitzgerald Comments on WVE FY2026 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Wave Life Sciences in a report released on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings of ($1.26) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $10.00 price objective on the stock. The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share.

Several other equities research analysts have also recently weighed in on WVE. Jefferies Financial Group initiated coverage on Wave Life Sciences in a report on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price objective for the company. Raymond James initiated coverage on Wave Life Sciences in a research report on Wednesday. They set an "outperform" rating and a $14.00 price objective for the company. Wall Street Zen cut Wave Life Sciences from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Wedbush started coverage on shares of Wave Life Sciences in a report on Tuesday, April 8th. They set an "outperform" rating and a $18.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Wave Life Sciences in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.50.

Wave Life Sciences Trading Up 1.5%

Shares of WVE stock traded up $0.11 during trading hours on Tuesday, reaching $7.34. The company's stock had a trading volume of 294,944 shares, compared to its average volume of 1,311,739. The stock has a market capitalization of $1.13 billion, a P/E ratio of -6.56 and a beta of -1.04. The firm's fifty day simple moving average is $6.44 and its 200 day simple moving average is $9.91. Wave Life Sciences has a one year low of $4.25 and a one year high of $16.74.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The business had revenue of $9.18 million for the quarter, compared to analysts' expectations of $11.65 million. During the same quarter in the previous year, the company earned ($0.24) earnings per share.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new position in Wave Life Sciences during the fourth quarter valued at approximately $40,000. Quarry LP bought a new stake in shares of Wave Life Sciences in the 4th quarter valued at approximately $62,000. KBC Group NV bought a new stake in Wave Life Sciences in the fourth quarter worth approximately $67,000. Summit Investment Advisors Inc. increased its holdings in shares of Wave Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock worth $119,000 after purchasing an additional 2,308 shares during the period. Finally, Westwood Wealth Management acquired a new position in Wave Life Sciences in the fourth quarter valued at about $124,000. 89.73% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the transaction, the director now directly owns 16,115 shares of the company's stock, valued at $157,443.55. The trade was a 39.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 29.10% of the stock is currently owned by company insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.